R. Salazar

TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

TL;DR: A higher frequency of ovarian cancer associated with mutations localized in the 5′ end of the BRCA1 gene is found, but there was no association between the prevalence of this type of cancer and mutations situated in the ovarian cancer cluster region (OCCR).

TL;DR: The results are consistent with those from a recent meta-analysis of practically all previous penetrance studies, suggesting that women with BRCA1 and BRCa2 mutations attending genetic counseling services in Spain have similar risks of breast and ovarian cancer to those published for other Caucasian populations.

TL;DR: The addition of pasireotide toEverolimus was not associated with the improvement in PFS compared with everolimus alone in this study, and further studies to delineate mechanisms by which SSAs slow tumor growth in NET are warranted.

TL;DR: Having a live-birth was associated with protection for BRCA1 mutation carriers and a strong and consistent protective effect of age at first birth was observed for parous carriers of mutations in both genes, and this trend was highly consistently observed for carriers of mutation in each gene.